Woman suffers painful breast lumps after receiving cadaver-derived filler amid legal fight
A Californian who paid $10,000 for the cadaver-derived filler AlloClae reports painful oil cysts and fat necrosis, while the product is entangled in a lawsuit between Tiger Aesthetics and the New York State Department of Health.
Nicole, a woman in her 40s from California, spent $10,000 on the off-the-shelf cadaver-derived filler AlloClae and now suffers from hard, pebble-like lumps and oil cysts in her breasts, a condition doctors describe as fat necrosis. Imaging performed between March and May revealed oversized granulomas that hinder clear assessment for potential malignancies. The controversy surrounding AlloClae intensified after the New York State Department of Health sued its maker, Tiger Aesthetics, alleging the company smuggled the product into the state via shipments to Connecticut and New Jersey.
Tiger Aesthetics counters that the denial of distribution licenses is unlawful and asserts the filler meets FDA regulations. While some plastic surgeons, such as Tommaso Adonna, caution that the allogeneic fat matrix may lack sufficient vascularity, others continue to offer the treatment to meet consumer demand. Ongoing legal proceedings focus on licensing and compliance, leaving patients like Nicole uncertain about long-term outcomes.
Why it matters
The case highlights risks of new cosmetic fillers and regulatory gaps that affect patient safety.
In this story